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230 females of childbearing age from four different towns in Oyo State were screened for rubella specific IgG antibody 
using a sandwich ELISA test kit. Rubella IgG was detected in 215 (93.5%) of the females. 96% of the non-pregnant, 
87.5% of the primigravida and 76% of the multigravida screened positive to the antibody. Ogbomoso, Ibadan, Oyo and 
Iseyin respectively had 96.1%, 94.2%, 90.5% and 88.2% of their samples positive for the rubella IgG antibody in them. 
It is imperative for the government to ensure that rubella vaccine is made available and routine so as to avert the risk 





Rubella is a universally endemic mild febrile disease 
difficult to diagnose clinically because of its mild 
symptoms and similarity to other diseases such as 
measles, scarlatina, infectious erythema, infectious 
mononucleosis and drug rash. Though of a 
worldwide distribution, clinically recognized disease 
occurs less frequently in tropical regions than in 
temperate zones (1). Humans are the only host of 
the virus and infection is by contact with 
nasopharyngeal secretions of infected persons, 
droplets spread or direct contact with patients. 
Gregg (2) discovered the teratogenic nature and the 
possibility of vertical transmission of rubella. When 
infection is in the first trimester, it is potent to 
produce a range of permanent congenital defects 
like deafness, mental retardation, cardiac 
abnormalities, and congenital cataracts (3). These 
conditions are collectively known as congenital 
rubella syndrome (CRS). Diabetes, thyroid disease 
and progressive rubella panencephalitis have been 
reported as late effects of CRS  ( 4). 
Incidence rates of rubella was reportedly high in 
children 5-9 years of age in 1969 (5) while in recent 
times, it has shifted to young adults and adolescents 
(6). Rubella surveillance based on clinical reports is 
not specific because of its mild nature and 
relatedness to some other viral infections (7). So, it 
is better done during rubella epidemic. Studies have 
been tending towards using other body fluids apart 
from sera for the screening. Laboratory diagnosis 
using saliva (7,), urine (8) and low avidity IgG and 
IgA tests (9) have been found to be reliable for the 
diagnosis of rubella infection. 
 
MATERIALS AND METHOD 
(a) Study Population 
Two hundred and thirty females of childbearing age 
consisting of 169 married and 61 non-married 
women from Ibadan, Oyo, Iseyin and Ogbomoso in 
Oyo State had their sera screened for rubella IgG 
antibody.  2ml venous blood samples were collected 
from each of the woman after ethical approval and 
 78
informed consents were obtained. The sera were 
frozen at -200 C until analyzed. 
 
(b) Method 
Rubella Specific IgG antibody in serum was 
detected with an enzyme linked immunosorbent 
assay (ELISA) kit (Human Gasellschaft for 
Biochemica and Diagnosdtica, mbh, Germany). The 
kit is a sandwich enzyme immunoassay designed to 
be used on serum samples of 100µl added to 
microtiter strip wells as a solid phase coated with 
purified rubella virus antigen (RVAg). Microplate 
incubation was at 370 C for 30 minutes, followed by 
washing, incubation for an additional 30 minutes 
with 100µl anti IgG conjugate, washing and 
development with substrate tetramethyl benzidine 
(TMB) for 15 minutes. The reaction was then 
stopped and the results read within 30 minutes. 
 
RESULTS 
215 (95.5%) of the females screened had detectable 
rubella specific IgG while 15 (6.5%) did not. In 
terms of age distribution, all the 11 females of ages 
40-45 years screened positive to the rubella IgG. 
This is closely followed by ages 35 – 39 years 
where 28 (91.3%) of the 69 samples from females of 
ages 25 – 29 years were seropositive to the rubella 
IgG (Table 1). Ibadan, Ogbomoso, Oyo and Iseyin 
were used for the study. Table 2 shows the 
prevalence of rubella in the towns of study. 
Of significance to this study are the 3 (4.9%) out of 
61 spinsters screened, 9 (6.8%) out of 133 pregnant 
women and 4 (4.12%) out of 97 non- pregnant 
women who had no detectable rubella IgG in them. 
 
Table 1: Age Distribution of rubella IgG antibody 
Age (Years) Total Sample Number –ve (%) Number +ve (%) 
15-19 13 1 (7.7) 12 (92.3) 
20-24 48 2 (4.2) 46 (95.8) 
25-29 69 6 (8.7) 63 (91.3) 
30-34 60 5 (8.3) 55 (91.7) 
35-39 29 1 (3.4) 28 (96.6) 
40-45 11 0 (0) 11 (100) 
Total 230   
 
Table 2:  Rubella IgG antibody Distribution in the study Towns 
Towns Total Sample Number –ve (%) Number +ve (%) 
Ibadan 120 7(5.8) 113 (94.2) 
Ogbomoso 51 2 (3.9) 49 (96.1) 
Oyo 42 4 (9.5) 38 (90.5) 




The role of antibody prevalence surveys in 
immunization programme development and 
refinement is now being generally appreciated. Such 
surveys are important for identifying target age 
groups for measles vaccination (10), providing data 
on the burden of disease from congenital rubella 
syndrome (11) and monitoring their respective 
control programmes. It has been a source of 
motivation and challenge for both the government 
and biomedical scientists to work towards 
prevention rather than curing certain viral infections. 
The absolute risk of CRS among children born to 
mothers infected during pregnancy varies widely in 
different studies. Miller et al (12) found the risk of 
congenital infection to be 81% and that of 
malformation 69% after confirmed maternal rubella 
in the first trimester. 
The seropositivity of 93.5% of the female subjects 
screened is more likely to be due to their exposure 
to the virus and reinfection rather than rubella 
vaccination as all the women screened knew nothing 
about rubella vaccine probably because it is not 
included in the routine immunization programme in 
Nigeria. There is an increase in the percentage of 
women with detectable rubella IgG antibody when 
the results of this study are compared with what 
Odelola (13) obtained where 70% of the women 
screened were seropositive for the rubella IgG 
antibody. This is likely due to increase in population 
and overcrowding. 
If the risk of congenital rubella infection is 81% and 
that of malformation is 69% (10), it implies that 
there is a high risk of CRS among the 4.9% negative 
spinsters, 6.8% pregnant women and 4.12% non 
pregnant women. The same is true of the 
multigravids who are still in their active 
reproductive stages with their ages ranging from 25 
– 34 years if they are infected in the first trimester of 
the next pregnancy. Also, the pregnant seronegative 
women who are mostly in their second trimester 
stand a 20% chance of infecting their fetuses with 
rubella if infected. The increasing detection of 
rubella IgG antibody in married women suggests 
that rubella virus is still in circulation in Oyo state. 
Considering the potential dangers of CRS, it is 
important that rubella vaccine be included in the 
routine immunization programme of the country as 
it confers a lifelong protection against the virus in 
women and children who are the ones really 
affected. 
As at 2002 when this work was done, the available 
data about the prevalence of rubella IgG in Nigeria 
were (13, 14, 15) all revealed that the virus was 
circulating then but now with this study, there is an 
increased seropositivity. This may be due to 
increasing population, poor hygiene, poverty and 
overcrowding. It is hoped that the virus will not 
mutate some day to become more virulent than it is 
today. If this happens, children and females will 
suffer for it. To avoid this, it is necessary to 
concentrate on sparsely populated areas where the 
dwellers are more seronegative than in densely 
populated areas and schoolgirls for routine rubella 
vaccination. The vaccine should also be made 
available and mandatory for all pregnant women in 
their antenatal clinics. Coupling strengthened 
immunization programme with regular surveillance 
and sensitization of the women about the virus will 
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